Chronic myeloid leukemia: Pathophysiology and therapeutics

Seth J. Corey, Jorge Cortes

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disorder -characterized by a translocation between the long arms of chromosomes 9 and 22. Often referred to as the Philadelphia (Ph) chromosome, this genetic rearrangement results in an oncogenic tyrosine kinase, Bcr-Abl. The disease may smolder for years before terminating in a blast crisis. Once curable, mostly with bone marrow transplantation and only seldom with interferon alpha-based therapy, its management has been radically changed with the introduction of imatinib mesylate, an orally available Abl kinase inhibitor, in 1998. More common in adults, only an estimated 50 pediatric cases occur annually in North America. The treatment of CML will remain in flux as second-generation Bcr-Abl kinase inhibitors are studied clinically. Because of its rarity in pediatrics, clinical insights must come from -experience with adult CML. CML serves as the paradigm of how molecular understanding of a cancer's pathophysiology can produce a revolutionary form of -targeted therapy, providing hope for those pediatric cancers with a well-defined genetic lesion.

Original languageEnglish (US)
Title of host publicationMolecularly Targeted Therapy for Childhood Cancer
PublisherSpringer New York
Pages139-153
Number of pages15
ISBN (Print)9780387690605
DOIs
StatePublished - Dec 1 2010
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Chronic myeloid leukemia: Pathophysiology and therapeutics'. Together they form a unique fingerprint.

  • Cite this

    Corey, S. J., & Cortes, J. (2010). Chronic myeloid leukemia: Pathophysiology and therapeutics. In Molecularly Targeted Therapy for Childhood Cancer (pp. 139-153). Springer New York. https://doi.org/10.1007/978-0-387-69062-9_8